Related Experiment Video
Updated: Jun 1, 2026
06:46
Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent
Published on: May 8, 2017
A Rationally Engineered MAGL-Activatable Fluorogenic Probe Enables Efficient Discovery of Anti-Inflammatory and
Lele Liu1,2, Shimin Hou1,2, Lin Chen2
1Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education, Pharmacy School of Shihezi University, Shihezi, Xinjiang 832003, China.
Journal of Medicinal Chemistry
|May 30, 2026
Summary
A new fluorogenic probe enables efficient discovery of MAGL inhibitors. These inhibitors show potential for treating inflammatory diseases and liver injury by reducing inflammation and protecting liver cells.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Discovery
Background:
- Monoacylglycerol lipase (MAGL) is a therapeutic target for inflammatory diseases and drug-induced hepatotoxicity.
- Efficient discovery of MAGL inhibitors is hampered by the lack of robust screening assays.
Purpose of the Study:
- Develop a high-performance MAGL-activatable fluorogenic probe for inhibitor screening.
- Identify novel MAGL inhibitors with anti-inflammatory and hepatoprotective properties.
Main Methods:
- Structural optimization of a luminescent scaffold to create the probe CN-2.
- Establishment of a CN-2-based high-throughput screening platform.
- In vitro and in vivo evaluation of identified MAGL inhibitors in cellular and organoid models.
Main Results:
- The developed probe CN-2 exhibited optimal signal enhancement, sensitivity, and kinetics.
- Three potent MAGL inhibitors (A5, A11, F10) were identified.
- Inhibitors demonstrated anti-inflammatory effects in macrophages and hepatoprotective effects against acetaminophen-induced liver injury.
Conclusions:
- A practical and efficient platform for discovering MAGL inhibitors was established.
- The identified MAGL inhibitors hold promise as novel anti-inflammatory and hepatoprotective agents.
- This work facilitates the development of new therapeutics for inflammatory conditions and liver diseases.
